Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsDRUGDOCS AIAboutNewsGlossaryContact
HomeDrugsAIAboutNewsGlossaryContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

AI

News

Sitagliptin and metformin hydrochloride

(Janumet®)

Janumet®

Drug updated on 9/4/2024

Dosage FormTablet (oral; sitagliptin/metformin hydrochloride 50 mg/500 mg); Tablet (oral; sitagliptin/metformin hydrochloride 50 mg/1000 mg)
Drug ClassDipeptidyl peptidase-4 inhibitors and metformin hydrochloride
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Janumet (sitagliptin and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • This summary is based on the review of three systematic review(s)/meta-analysis(es). [1-3]
  • HbA1C Reduction: Once-weekly Semaglutide significantly improved HbA1C (WMD: -0.98; 95% CI: -1.28, -0.69), with saxagliptin+metformin (MD: -1.91%; 95% CI: -2.85%, -0.97%), liraglutide+metformin (MD: -1.45%; 95% CI: -1.65%, -1.26%), and liraglutide (MD: -0.90%; 95% CI: -1.35%, -0.45%) also showing significant reductions. Gemigliptin had comparable effectiveness to active comparators (MD: 0.09%; 95% CI: -0.06 to 0.23).
  • Blood Pressure and Body Weight: Semaglutide significantly reduced systolic blood pressure (WMD: -3.73; 95% CI: -5.42, -2.04) and diastolic blood pressure (WMD: -0.66; 95% CI: -1.02, -0.29), as well as body weight (WMD: -3.17; 95% CI: -3.84, -2.49).
  • Glycaemic Targets: Gemigliptin achieved superior outcomes in reaching HbA1C <7% compared to placebo/control at 12 weeks (OR: 5.91; 95% CI: 1.34 to 26.08) and 24 weeks (OR: 4.48; 95% CI: 2.09 to 9.60), but was comparable to active comparators (OR: 0.92; 95% CI: 0.52 to 1.63).
  • Semaglutide was associated with an increased rate of total adverse events and premature treatment discontinuation compared to sitagliptin, along with an observed increase in pulse rate (WMD: 3.33; 95% CI: 1.61, 5.06; p-value: <0.00001).
  • Liraglutide+metformin was linked to significant adverse effects, such as abdominal pain, while other treatment combinations, including sitagliptin+metformin, did not show significant differences in the incidence of adverse events.
  • There is no population-type or subgroup information available in the reviewed studies.